Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN7 | P35236 | 5/20 | 0.46 |
| ▸ | HMGCR | P04035 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12541573 | 1.00 | PTPN7 (0.46) | PTPN7HMGCRTSHRTHRBRECQL | |
| SCHEMBL3461762 | 1.00 | PTPN7 (0.46) | PTPN7HMGCRTSHRTHRBRECQL | |
| SCHEMBL313520 | 1.00 | PTPN7 (0.46) | PTPN7HMGCRTSHRTHRBRECQL | |
| SCHEMBL455197 | 1.00 | PTPN7 (0.46) | PTPN7HMGCRTSHRTHRBRECQL | |
| SCHEMBL3248000 | 1.00 | PTPN7 (0.46) | PTPN7HMGCRTSHRTHRBRECQL | |
| SCHEMBL12541540 | 1.00 | PTPN7 (0.46) | PTPN7HMGCRTSHRTHRBRECQL | |
| SCHEMBL3281607 | 1.00 | PTPN7 (0.46) | PTPN7HMGCRTSHRTHRBRECQL | |
| SCHEMBL184032 | 1.00 | PTPN7 (0.46) | PTPN7HMGCRTSHRTHRBRECQL | |
| SCHEMBL1792259 | 1.00 | PTPN7 (0.46) | PTPN7HMGCRTSHRTHRBRECQL | |
| SCHEMBL3461057 | 1.00 | PTPN7 (0.46) | PTPN7HMGCRTSHRTHRBRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110475783-B | Cationic ruthenium complex, preparation method and application thereof | 高砂香料工业株式会社 | 2022-10-21 | — | — | CN | disclosed |
| EP-3135681-B1 | RUTHENIUM COMPLEX, METHOD FOR PRODUCING SAME, AND USE OF SAME | TAKASAGO PERFUMERY CO LTD (JP) | 2020-08-19 | — | — | EP | disclosed |
| CN-107075789-B | Oil agent for carbon fiber precursor acrylic fiber, composition and treatment liquid thereof, and carbon fiber precursor acrylic fiber bundle | 三菱化学株式会社 | 2020-01-07 | — | — | CN | disclosed |
| US-10059729-B2 | Ruthenium complex, method for producing same, and use of same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2018-08-28 | — | — | US | disclosed |
| US-10005718-B2 | Catalyst, and method for producing oxidation product | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-06-26 | — | — | US | disclosed |
| EP-2940004-B1 | METHOD FOR PRODUCING OXIME | SUMITOMO CHEMICAL CO (JP) | 2017-09-13 | — | — | EP | disclosed |
| CN-104870420-B | The manufacture method of oxime | 住友化学株式会社 | 2017-06-27 | — | — | CN | disclosed |
| US-9656950-B2 | Method for producing oxime | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-05-23 | — | — | US | disclosed |
| EP-3135681-A1 | RUTHENIUM COMPLEX, METHOD FOR PRODUCING SAME, AND USE OF SAME | Takasago International Corporation (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-20170044196-A1 | RUTHENIUM COMPLEX, METHOD FOR PRODUCING SAME, AND USE OF SAME | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2017-02-16 | — | — | US | disclosed |
| US-20100279311-A1 | METHOD FOR SCREENING OF CELL-PROTECTING AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-04 | — | — | US | disclosed |
| EP-2226632-A1 | METHOD FOR SCREENING OF CELL-PROTECTING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2010-09-08 | — | — | EP | disclosed |
| US-7704939-B2 | Surfactant | SANYO CHEMICAL INDUSTRIES, LTD. (JP) | 2010-04-27 | — | — | US | disclosed |
| US-20070167343-A1 | neutralized salt including alkylbenzenesulphonates (toluenesulfonic acid guanidine salt, toluenesulfonic acid DBU salt, toluenesulfonic acid DBN salt) for cleaning electonics | SANYO CHEMICAL INDUSTRIES, LTD. (JP) | 2007-07-19 | — | — | US | disclosed |
| US-7232926-B2 | Method for the production of sulphamic acid halogenides | BASF AKTIENGESELLSCHAFT (DE) | 2007-06-19 | — | — | US | disclosed |
| US-20050159622-A1 | Method for the production of sulphamic acid halogenides | BASF AKTIENGESELLSCHAFT (DE) | 2005-07-21 | — | — | US | disclosed |
| EP-0643119-B1 | Trans-olefin compounds, method for production thereof, liquid crystal composition containing the same as active ingredient, and liquid crystal element using said composition | SUMITOMO CHEMICAL CO (JP) | 2000-04-26 | — | — | EP | disclosed |
| US-6030546-A | FERROELECTRIC PHASE; LOW VISCOSITY;, THERMOSENSITIVITY OVER A BROAD AND EXHIBITS A LARGE TILT ANGLE AND A HIGH-SPEED RESPONSE PROPERTY;CHEMICAL INTERMEDIATES FOR PESTICIDES, DRUGS AND LIQUID CRYSTALS; BORIDING AND HYDROLYSIS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-02-29 | — | — | US | disclosed |
| US-5707547-A | CONTAINING FLUORINATED BENZENE OR NAPHTHALENE RINGS AND/OR NITROGEN CONTAINING HETEROCYCLES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-01-13 | — | — | US | disclosed |
| EP-0643119-A1 | Trans-olefin compounds, method for production thereof, liquid crystal composition containing the same as active ingredient, and liquid crystal element using said composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1995-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279311-A1 | METHOD FOR SCREENING OF CELL-PROTECTING AGENT | HSF1, HSP90AB1, HSP90AA1 | PTPN7 3276/4885HMGCR 3259/4885TSHR 3403/4885 |
| US-10059729-B2 | Ruthenium complex, method for producing same, and use of same | ADH1C, PNPO, PNP | PTPN7 1187/4885HMGCR 2014/4885TSHR 2992/4885 |
| US-20170044196-A1 | RUTHENIUM COMPLEX, METHOD FOR PRODUCING SAME, AND USE OF SAME | ADH1C, PNPO, PNP | PTPN7 1187/4885HMGCR 1988/4885TSHR 3009/4885 |
| US-20050159622-A1 | Method for the production of sulphamic acid halogenides | AS3MT, ARSA, SRM | PTPN7 2217/4885HMGCR 4397/4885TSHR 1055/4885 |
| US-10005718-B2 | Catalyst, and method for producing oxidation product | PPOX, HAO2, SCO2 | PTPN7 3325/4885HMGCR 782/4885TSHR 3391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.